Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:AL Amyloidosis · Phase 3 · investigational in the US
Also approved (2)
- Treatment of relapsed or refractory multiple myeloma
- Multiple Myeloma Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1). in as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. Smouldering multiple myeloma Darzalex as monotherapy is indicated for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma. Light chain (AL) amyloidosis Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02076009 NCT02076009 · Multiple Myeloma This open-label, randomized Phase 3 trial (POLLUX) assigned 569 patients with relapsed or refractory multiple myeloma to lenalidomide and dexamethasone with or without daratumumab. The primary endpoint was progression-free survival. At the protocol-specified interim analysis, daratumumab significantly lowered the risk of progression or death (hazard ratio 0.37, 95% CI 0.27 to 0.52, P<0.001), so the primary was met. Source: the peer-reviewed paper (Dimopoulos et al., N Engl J Med 2016). Registry: NCT02076009 | 3 | Progression-free Survival (PFS) (From randomization to either disease progression or death whichever occurs first (up to 21 months)) 2016-03-07 | Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016). | Partial signal | link ↗ |
View 6 more trials
NCT02136134 NCT02136134 · Multiple Myeloma This open-label, randomized Phase 3 trial (CASTOR) assigned 498 patients with relapsed or refractory multiple myeloma to bortezomib and dexamethasone with or without daratumumab. The primary endpoint was progression-free survival. At the prespecified interim analysis, daratumumab significantly lowered the risk of progression or death (hazard ratio 0.39, 95% CI 0.28 to 0.53, P<0.001), so the primary was met. Source: the peer-reviewed paper (Palumbo et al., N Engl J Med 2016). Registry: NCT02136134 | 3 | Progression-free Survival (PFS) (From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)) 2016-01-11 | Progression-free survival at the interim analysis: median not reached with daratumumab plus bortezomib/dexamethasone vs 7.2 months with bortezomib/dexamethasone (hazard ratio 0.39; 95% CI 0.28 to 0.53; P<0.001) (CASTOR, N Engl J Med 2016). | Partial signal | link ↗ |
NCT03301220 NCT03301220 · Smoldering Multiple Myeloma Participants were randomized to daratumumab (194) or active monitoring (196), and the primary clinical endpoint of progression-free survival was met, favoring daratumumab (HR 0.49, 95% CI 0.36–0.67; p<0.0001). The trial provides meaningful comparative evidence but was not blinded, so it is rated moderate rather than strong. Registry: NCT03301220 | 3 | Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC) (From randomization (Day -5) up to 77 months) 2024-05-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
AURIGA NCT03901963 · Multiple Myeloma The trial was randomized and actively controlled, with 99 participants assigned to daratumumab plus lenalidomide and 101 to lenalidomide alone, but treatment was open-label. Its primary endpoint, MRD conversion at 12 months, favored daratumumab plus lenalidomide (50.5% vs 18.8%; p<0.0001), while MRD is a biomarker-based surrogate rather than a direct clinical outcome. Registry: NCT03901963 | 3 | Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months) 2024-04-04 | Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8) | Partial signal | link ↗ |
NCT01985126 NCT01985126 · Multiple Myeloma Registry: NCT01985126 | 2 | Percentage of Participants With Overall Response (Up to 14.4 Months) 2015-01-09 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT00574288 NCT00574288 · Multiple Myeloma Registry: NCT00574288 | 2 | Number of Participants With Adverse Events (Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)) 2015-01-09 | Label-reported response: Overall response rate was 36% (95% CI: 21.6, 52.0%) with 1 CR and 3 VGPR. | not yet graded | link ↗ |
NCT01998971 NCT01998971 · Multiple Myeloma Registry: NCT01998971 | 1 | Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) (Up to 30 days after the last dose of study medication); Number of participants affected by dose-limiting toxicities (Up to 30 days after the last dose of study medication) 2019-01-31 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (50)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (173)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (41)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (59)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (35)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
Other CD38 drugs
Isatuximab, BCD-264, CT-P44, Felzartamab, HLX15 and 7 more. Compare all 13 CD38 drugs
This mechanism is crowded: 13 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Daratumumab: this drug | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Anselamimab (Amlypave) | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mezagitamab | Phase 3(overall) | Monoclonal antibody | CD38 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Birtamimab | Discontinued | Monoclonal antibody | Misfolded immunoglobulin light chain (AL amyloid) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(130 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Daratumumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (9)
November 2026 (3)
What to watch
What to watch
What to watch
December 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (46)
January 2027 (3)
What to watch
What to watch
What to watch
February 2027 (2)
March 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (4)
What to watch
What to watch
What to watch
What to watch
May 2027 (4)
What to watch
What to watch
What to watch
What to watch
June 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (4)
What to watch
What to watch
What to watch
What to watch
August 2027 (1)
What to watch
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (2)
November 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
December 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (22)
February 2028 (3)
What to watch
What to watch
What to watch
March 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (2)
July 2028 (2)
August 2028 (3)
What to watch
What to watch
What to watch
September 2028 (2)
October 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (19)
January 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2029 (1)
What to watch
April 2029 (2)
May 2029 (3)
What to watch
What to watch
What to watch
July 2029 (2)
What to watch
What to watch
August 2029 (1)
October 2029 (1)
What to watch
November 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (8)
2031 (9)
January 2031 (1)
What to watch
February 2031 (1)
What to watch
March 2031 (1)
What to watch
April 2031 (2)
May 2031 (2)
June 2031 (1)
What to watch
October 2031 (1)
What to watch
2032 (4)
September 2032 (2)
2033 (4)
2034 (1)
August 2034 (1)
What to watch
2035 (2)
September 2035 (1)
What to watch
December 2035 (1)
What to watch
2036 (2)
2037 (1)
January 2037 (1)
What to watch
2041 (1)
March 2041 (1)
What to watch
2042 (1)
February 2042 (1)
What to watch
2044 (1)
September 2044 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent